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rence pour le syndrome de Marfan et apparentés, Paris, France – (8) CHU
Rennes, Hôpital Sud, Génétique, Rennes, France – (9) CHU Dijon, Hôpital
des Enfants, Pédiatrie – Génétique clinique, Dijon, France – (10) APHP-
Hôpital Ambroise Paré, Pédiatrie, Boulogne, France – (11) CHU Bordeaux,
M3C, Paediatric and Congenital Cardiology, Bordeaux, France – (12)
APHM-CHU la Timone Enfant, Génétique Clinique, Marseille, France
Objectives: Risk markers of cardio-vascular events in children with Marfan
syndrome remain little known. We assessed the prognostic value of aortic root
z-score in patients with Marfan syndrome diagnosed during childhood.
Methods: From the French multicenter database, 457 patients with Marfan
syndrome, diagnosed before 18 y.o., were prospectively included in this
cohort study. Echocardiographic measurements of aortic root diameters were
performed at each visit. We calculated the Z-score of aortic root measure-
ments using the Bichat formula. Mean z-score was defined as the mean of the
z-score (MeanZS15) calculated for each measurement before the age of 16.
Results: Median age at end of FU was 15.9years (interquartile 10.9-20.3).
FU was complete for 69.5% of patients. Median FU was 4.6years. A cardio-
vascular event occurred in 17 patients (3.7%, prophylactic aortic surgery
n=14, aortic dissection n=1 and deaths n=2). Survival free of cardiac events
was 85.1% in patients with a meanZS15 of the Valsalva diameter <3 and
56.4% in patients with a meanZS15 of the Valsalva diameter ≥3 (p<0.0001 by
log-rank test). In univariate analysis, Valsalva meanZS15 ≥3, age at inclusion
in the database, a lower heart rate and an increased arm/height ratio were asso-
ciated with an increasing risk of cardiac events (p<0.0001, p=0.04, p=0.01 and
p=0.04 respectively). After multivariate adjustment using a cox proportional
hazards model, only Valsalva meanZS15 ≥3 and lack of FBN1 or TGBB
mutation identified were associated with an increasing risk of cardiac events,
p<0.0001 and p=0.04 respectively).
Conclusion: Valsalva meanZS15 may help to identify high-risk children.
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Background: Despite the absence of randomized studies comparing mitral
valve (MV) repair and replacement, international guidelines strongly recom-
mend MV repair as the optimal surgical treatment for severe degenerative
mitral regurgitation (dMR). Yet, the level of evidence supporting these recom-
mendations is low, owing to the lack of available clinical trial data. In this
context, analysis of large multicenter registries becomes critical.
Objective: To compare very long-term survival among patients (pts)
undergoing MV repair versus replacement for the treatment of severe dMR
using the technique of propensity score (PS) matching to reduce bias in non-
randomized cohorts.
Methods: The Mitral Regurgitation International DAtabase (MIDA) is a
prospective multicenter registry that includes 2,569 consecutive pts with dMR,
who were recruited in 6 tertiary centers (France, Italy, Belgium, and the
United States) between 1980 and 2005. Among these, we identified 1,922 pts
who underwent mitral surgery, including 1,709MV repairs and 213MV
replacements. We compared operative mortality and overall survival in both
the entire study population and in 615 PS-matched (2:1) pts.
Results: Operative mortality was lower after MV repair than after MV
replacement, both in the entire population (2 vs 7%; p=0.001) and in the PS-
matched pts (4 vs 8%; p=0.04). Similarly, 20-year survival was better after
MV repair than after MV replacement, both in the entire population (46%
[(95% CI, 39%-52%] vs 23% [95% CI, 14%-32%], p<0.001) and in the PS-
matched pts (41% [95% CI, 28%-54%] vs 24% [95% CI, 14%-33%],
p<0.001). Similar results were obtained in pts aged < 65 years (p<0.005), 65-
74 years (p<0.001) and ≥75 years (p<0.001). 
Conclusions: Among registry pts with dMR, performance of MV repair
resulted in lower operative mortality and greater long-term survival compared
to MV replacement, thus supporting current international recommendations.
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